File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Significance of Size of Lymph Node Metastasis on Postsurgical Stimulated Thyroglobulin Levels After Prophylactic Unilateral Central Neck Dissection in Papillary Thyroid Carcinoma

TitleSignificance of Size of Lymph Node Metastasis on Postsurgical Stimulated Thyroglobulin Levels After Prophylactic Unilateral Central Neck Dissection in Papillary Thyroid Carcinoma
Authors
KeywordsMedicine & Public Health
Surgical Oncology
Oncology
Surgery
Issue Date2012
PublisherSpringer New York
Citation
Annals of Surgical Oncology, 2012, v. 19 n. 11, p. 3472-3478 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/147116
ISSN
2015 Impact Factor: 3.655
2015 SCImago Journal Rankings: 1.902
ISI Accession Number ID
References

Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary and follicular thyroid carcinoma: implications for cancer staging. Ann Surg Oncol. 2007;14:730–8. doi: 10.1245/s10434-006-9207-5

Machens A, Hauptmann S, Dralle H. Lymph node dissection in the lateral neck for completion in central node-positive papillary thyroid cancer. Surgery. 2009;145:176–81. doi: 10.1016/j.surg.2008.09.003

Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid carcinoma. Surgery. 2006;140:1000–7. doi: 10.1016/j.surg.2006.08.001

So YK, Seo MY, Son YI. Prophylactic central lymph nodes dissection for clinically node-negative papillary thyroid microcarcinoma: influence on serum thyroglobulin level, recurrence rate, and postoperative complication. Surgery. 2012;151:192–8. doi: 10.1016/j.surg.2011.02.004

Lang BH, Wong KP, Wan KY, Lo CY. Impact of routine unilateral central neck dissection on preablative and postablative stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma. Ann Surg Oncol. 2012;19:60–7. doi: 10.1245/s10434-011-1833-x

Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery. 2010;148:1100–6. doi: 10.1016/j.surg.2010.09.019

Bardet S, Malville E, Rame JP, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol. 2008;158:551–60. doi: 10.1530/EJE-07-0603

Mercante G, Frasoldati A, Pedroni C, et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid. 2009;19:707–16. doi: 10.1089/thy.2008.0270

Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135:139–48. doi: 10.1016/S0039-6060(03)00384-2

Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007;245:366–78. doi: 10.1097/01.sla.0000250445.92336.2a

Cranshaw IM, Carnaille B. Micrometastases in thyroid cancer. An important finding? Surg Oncol. 2008;17:253–8. doi: 10.1016/j.suronc.2008.04.005

Caron NR, Clark OH. Papillary thyroid cancer: surgical management of lymph node metastases. Curr Treat Options Oncol. 2005;6:311–22. doi: 10.1007/s11864-005-0035-9

Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90:5723–9. doi: 10.1210/jc.2005-0285

Teixeira G, Teixeira T, Gubert F, Chikota H, Tufano R. The incidence of central neck micrometastatic disease in patients with papillary thyroid cancer staged preoperatively and intraoperatively as N0. Surgery. 2011;150:1161–7. doi: 10.1016/j.surg.2011.09.019

Cooper DS, Doherty GM, Hauger BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214. doi: 10.1089/thy.2009.0110

Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:1440–5. doi: 10.1210/jc.2004-1771

Giovanella L, Ceriani L, Suriano S, Ghelfo A, Maffioli M. Thyroglobulin measurement before rh-TSH-aided 131I ablation in detecting metastases form differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2008;69:659–63. doi: 10.1111/j.1365-2265.2008.03244.x

Lang B, Lo CY, Chan WF, Lam KY, Wan KY. Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability. Ann Surg Oncol. 2007;14:1551–9. doi: 10.1245/s10434-006-9242-2

Lang BH, Wong KP, Wan KY, Lo CY. Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection. Ann Surg Oncol. 2012;19:1257–63. doi: 10.1245/s10434-011-2105-5

Takada H, Kikumori T, Imai T, Sawaki M, Shibata A, Kiuchi T. Patterns of lymph node metastases in papillary thyroid carcinoma: results from consecutive bilateral cervical lymph node dissection. World J Surg. 2011;35:1560–6. doi: 10.1007/s00268-011-1133-4

Kloos RT, Mazzaferri EL. A single recombinant human thyrotrophin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab. 2005;90:5047–57. doi: 10.1210/jc.2005-0492

Castagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab. 2008;93:76–81. doi: 10.1210/jc.2007-1404

 

DC FieldValueLanguage
dc.contributor.authorLang, BHHen_US
dc.contributor.authorTang, AHen_US
dc.contributor.authorWong, KPen_US
dc.contributor.authorShek, TWen_US
dc.contributor.authorWan, KYen_US
dc.contributor.authorLo, CYen_US
dc.date.accessioned2012-05-28T08:18:17Z-
dc.date.available2012-05-28T08:18:17Z-
dc.date.issued2012en_US
dc.identifier.citationAnnals of Surgical Oncology, 2012, v. 19 n. 11, p. 3472-3478en_US
dc.identifier.issn1068-9265en_US
dc.identifier.urihttp://hdl.handle.net/10722/147116-
dc.languageengen_US
dc.publisherSpringer New Yorken_US
dc.relation.ispartofAnnals of Surgical Oncologyen_US
dc.rightsThe Author(s)en_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong Licenseen_US
dc.subjectMedicine & Public Healthen_US
dc.subjectSurgical Oncologyen_US
dc.subjectOncologyen_US
dc.subjectSurgeryen_US
dc.titleSignificance of Size of Lymph Node Metastasis on Postsurgical Stimulated Thyroglobulin Levels After Prophylactic Unilateral Central Neck Dissection in Papillary Thyroid Carcinomaen_US
dc.typeArticleen_US
dc.identifier.openurlhttp://www.springerlink.com/link-out/?id=2104&code=XT83154032431K3R&MUD=MPen_US
dc.description.naturepublished_or_final_versionen_US
dc.identifier.doi10.1245/s10434-012-2385-4en_US
dc.identifier.pmid22565664-
dc.identifier.scopuseid_2-s2.0-84868204172en_US
dc.identifier.hkuros199993-
dc.identifier.hkuros248810-
dc.relation.referencesCancer incidence and mortality in Hong Kong, 1983–2006. Hong Kong Cancer Registry, Hong Kong. http://www3.ha.org.hk/cancereg/e_stat.asp. Accessed 15 Dec 2011.en_US
dc.relation.referencesLang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary and follicular thyroid carcinoma: implications for cancer staging. Ann Surg Oncol. 2007;14:730–8.en_US
dc.relation.referencesdoi: 10.1245/s10434-006-9207-5en_US
dc.relation.referencesMachens A, Hauptmann S, Dralle H. Lymph node dissection in the lateral neck for completion in central node-positive papillary thyroid cancer. Surgery. 2009;145:176–81.en_US
dc.relation.referencesdoi: 10.1016/j.surg.2008.09.003en_US
dc.relation.referencesSywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid carcinoma. Surgery. 2006;140:1000–7.en_US
dc.relation.referencesdoi: 10.1016/j.surg.2006.08.001en_US
dc.relation.referencesSo YK, Seo MY, Son YI. Prophylactic central lymph nodes dissection for clinically node-negative papillary thyroid microcarcinoma: influence on serum thyroglobulin level, recurrence rate, and postoperative complication. Surgery. 2012;151:192–8.en_US
dc.relation.referencesdoi: 10.1016/j.surg.2011.02.004en_US
dc.relation.referencesLang BH, Wong KP, Wan KY, Lo CY. Impact of routine unilateral central neck dissection on preablative and postablative stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma. Ann Surg Oncol. 2012;19:60–7.en_US
dc.relation.referencesdoi: 10.1245/s10434-011-1833-xen_US
dc.relation.referencesHughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery. 2010;148:1100–6.en_US
dc.relation.referencesdoi: 10.1016/j.surg.2010.09.019en_US
dc.relation.referencesBardet S, Malville E, Rame JP, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol. 2008;158:551–60.en_US
dc.relation.referencesdoi: 10.1530/EJE-07-0603en_US
dc.relation.referencesMercante G, Frasoldati A, Pedroni C, et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid. 2009;19:707–16.en_US
dc.relation.referencesdoi: 10.1089/thy.2008.0270en_US
dc.relation.referencesSugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135:139–48.en_US
dc.relation.referencesdoi: 10.1016/S0039-6060(03)00384-2en_US
dc.relation.referencesLang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007;245:366–78.en_US
dc.relation.referencesdoi: 10.1097/01.sla.0000250445.92336.2aen_US
dc.relation.referencesCranshaw IM, Carnaille B. Micrometastases in thyroid cancer. An important finding? Surg Oncol. 2008;17:253–8.en_US
dc.relation.referencesdoi: 10.1016/j.suronc.2008.04.005en_US
dc.relation.referencesCaron NR, Clark OH. Papillary thyroid cancer: surgical management of lymph node metastases. Curr Treat Options Oncol. 2005;6:311–22.en_US
dc.relation.referencesdoi: 10.1007/s11864-005-0035-9en_US
dc.relation.referencesLeboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90:5723–9.en_US
dc.relation.referencesdoi: 10.1210/jc.2005-0285en_US
dc.relation.referencesTeixeira G, Teixeira T, Gubert F, Chikota H, Tufano R. The incidence of central neck micrometastatic disease in patients with papillary thyroid cancer staged preoperatively and intraoperatively as N0. Surgery. 2011;150:1161–7.en_US
dc.relation.referencesdoi: 10.1016/j.surg.2011.09.019en_US
dc.relation.referencesCooper DS, Doherty GM, Hauger BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.en_US
dc.relation.referencesdoi: 10.1089/thy.2009.0110en_US
dc.relation.referencesKim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:1440–5.en_US
dc.relation.referencesdoi: 10.1210/jc.2004-1771en_US
dc.relation.referencesHeemstra KA, Liu YY, Stokkel M, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2007;66:58–64.en_US
dc.relation.referencesGiovanella L, Ceriani L, Suriano S, Ghelfo A, Maffioli M. Thyroglobulin measurement before rh-TSH-aided 131I ablation in detecting metastases form differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2008;69:659–63.en_US
dc.relation.referencesdoi: 10.1111/j.1365-2265.2008.03244.xen_US
dc.relation.referencesLang B, Lo CY, Chan WF, Lam KY, Wan KY. Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability. Ann Surg Oncol. 2007;14:1551–9.en_US
dc.relation.referencesdoi: 10.1245/s10434-006-9242-2en_US
dc.relation.referencesLang BH, Wong KP, Wan KY, Lo CY. Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection. Ann Surg Oncol. 2012;19:1257–63.en_US
dc.relation.referencesdoi: 10.1245/s10434-011-2105-5en_US
dc.relation.referencesTakada H, Kikumori T, Imai T, Sawaki M, Shibata A, Kiuchi T. Patterns of lymph node metastases in papillary thyroid carcinoma: results from consecutive bilateral cervical lymph node dissection. World J Surg. 2011;35:1560–6.en_US
dc.relation.referencesdoi: 10.1007/s00268-011-1133-4en_US
dc.relation.referencesWong KP, Lang BH. The role of prophylactic central neck dissection in differentiated thyroid carcinoma: issues and controversies. J Oncol. 2011;2011:127929.en_US
dc.relation.referencesKloos RT, Mazzaferri EL. A single recombinant human thyrotrophin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab. 2005;90:5047–57.en_US
dc.relation.referencesdoi: 10.1210/jc.2005-0492en_US
dc.relation.referencesCastagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab. 2008;93:76–81.en_US
dc.relation.referencesdoi: 10.1210/jc.2007-1404en_US
dc.identifier.spage3472en_US
dc.identifier.epage3478en_US
dc.identifier.eissn1534-4681en_US
dc.identifier.isiWOS:000308737100026-
dc.description.otherSpringer Open Choice, 28 May 2012en_US
dc.identifier.citeulike10665357-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats